ENDOSCOPY
ANAESTHESIA &
PATIENT MONITORING
SOLUTIONS
Ambu’s Endoscopy Solutions business continued to be
The pulmonology business group posted 8.5% organic
revenue growth, resulting in a last-twelve-months rolling
growth of 10.4%, with solid growth across all solutions
and geographies. The flu season had a small positive
impact on the growth overall. Specifically, the ICU saw
increased activity from the strong flu season, however,
both operating rooms and endoscopy suites were more
or less unaffected. Additionally, the pulmonology growth
in Q2 was negativetely affected by a substantial order
placement in Q1, with customers purchasing in expecta-
tion of a severe flu season.
Ambu’s Anaesthesia & Patient Monitoring business
accounted for 40% of the company’s total revenue in Q2
2024/25. The revenue grew organically by 9.8% (7.0%),
primarily driven by price increases and solid volume
growth, with both the Anaesthesia business group and the
Patient Monitoring business group contributing to the
growth.
the biggest revenue contributor in Q2 2024/25. It
accounted for 60% of the total revenue, with an organic
revenue growth of 13.1% (22.3%). Ambu experienced
growth across both business groups in Endoscopy
Solutions, mainly driven by continued growth of existing
solutions in a high-growth market, with existing and new
customers.
Drivers of the quarter
Drivers of the quarter
Overall, the growth of the Anaesthesia & Patient
Monitoring business was driven by price increases and
solid volume growth.
The Urology, ENT (ear-nose-throat) and GI (gastro-
enterology) business group posted 18.3% organic
revenue growth, resulting in a last-twelve-months rolling
growth of 23.4%. The growth was primarily driven by
continued penetration of the Ambu® aScope™ 4 port-
folio, with new and existing customers. The quarter saw
slower temporary growth, compared to previous
quarters, driven by new competition extending the sales
cycles. Although the Ambu® aScope™ 5 Uretero and
Ambu® aScope™ 5 Cysto HD were launched in Q1 with
positive momentum, the revenue impact of these new
solutions was limited in Q2, as expected. Overall, Ambu
remains confident in the long-term performance of this
business group, due to its advanced and extended
solutions portfolio.
Recent developments in new solutions
In Q2, Ambu began the initial commercialisation of its
new video laryngoscopy solution Ambu® SureSight™
Connect, receiving positive feedback from customers.
While this supports future pulmonology growth,
meaningful revenue will take time to materialise.
Ambu commercially launched its ureteroscopy solution,
Ambu® aScope™ 5 Uretero, at the start of the 2024/25
financial year, receiving positive feedback. During this
early commercial launch phase, Ambu has prioritised a
focused ramp-up of production to secure high levels of
both product quality and cost efficiency. As expected, the
revenue impact remains limited during this phase, as the
solution represents a new clinical setting with distinct
customer needs and a refined commercial approach.
Ambu remains committed to the solution’s strong
growth prospects.
As previously announced, Ambu has carried out strategic
initiatives to increase profitability by raising prices in
selected low-margin areas.
Most of the contract negotiations were completed by the
end of Q2 2023/24, resulting in a strong year-over-year
impact from price increases in H1 2024/25.
This contributed positively to the overall growth of the
Anaesthesia & Patient Monitoring business, surpassing the
long-term market growth projection of 2-4%.
GI posted high double-digit growth as well, however, the
business area remains a smaller part of Ambu’s busi-
ness. It was mainly driven by Ambu’s gastroscopy solu-
tions, Ambu® aScope™ Gastro and Ambu® aScope™
Gastro Large, both in integration with the digital endo-
scopy system, Ambu® aBox™ 2. Among other proce-
dures, the two gastroscopy solutions target specific
needs for bleed management.
Finally, Ambu strengthened its urology portfolio with the
CE mark expansion of aScope™ 5 Cysto HD, enabling
urologists to also perform cysto-nephroscopy proce-
dures, a niche procedure within urology.
Q2 organic
revenue growth
Q2 organic
revenue growth
Company announcement no. 13 2024/25 | 7 May 2025
5
